Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COMMONS BROTHERS TO ACQUIRE KRELITZ AND NORTHERN DRUG

This article was originally published in The Tan Sheet

Executive Summary

COMMONS BROTHERS TO ACQUIRE KRELITZ AND NORTHERN DRUG under a proposal approved by the Krelitz board on July 23. Finalization of the agreements "is subject to certain conditions, including the execution of a definitive acquisition agreement, approval by the shareholders of Krelitz, the satisfactory conclusion of [Common Brothers'] due diligence investigation and the absence of adverse changes between Krelitz' fiscal year end and closing, among others," Krelitz said. New York City-based wholesaler Commons Brothers (through its corporate parent CBI Holding) moved to acquire Krelitz and Northern Drug after the two Minnesota wholesalers had agreed to merge. Northern Drug had proposed to pay $ 4-5 mil. for Krelitz under an agreement in principle announced June 18. "The letter of intent previously announced between Krelitz and Northern Drug is expected to be terminated by mutual agreement," the companies said. Commons Brothers' purchase of Krelitz will be "on generally the same terms and conditions as those proposed by Northern Drug," Krelitz said. In a separate transaction, CBI signed a letter of intent to acquire Northern for an undisclosed amount. Through the acquisitions, Commons Brothers will be adding approximately $ 250 mil.- $ 275 mil. in sales and will expand its wholesaling operations from the Northeast into the upper Midwest. Krelitz reported sales of $ 249.6 mil. in fiscal 1992 (ended May 2, 1992), a decrease of 2%. Through the first nine months of fiscal 1993, Krelitz sales were $ 161.5 mil., down 13.6%. The company has posted losses since fiscal 1991. Its net loss for fiscal 1992 was $ 3.8 mil. The Krelitz family owns more than 50% of the outstanding shares of the company. Former National Wholesale Druggists Association Chairman Barry Krelitz is president and CEO. Krelitz operates through Twin City Wholesale Drug Company in Minneapolis. Privately held Northern Drug, based in Duluth, has annual sales of approximately $ 50 mil. to its 250 accounts. The wholesaler is owned by the Goldfine family, with NWDA board member Steven Goldfine serving as president. "Krelitz and Northern will continue to be operated under existing management," the companies said. Commons Brothers, also privately held, bills itself as "the nation's ninth largest drug wholesaler." The firm has distribution centers in Elmsford and Freeport, N.Y. and Harrisburg, Penn. Commons Brothers had sales of $ 370 mil. for the fiscal year ended April 1991 and subsequently acquired another Northeastern wholesaler, Granain, which had sales of $ 110 mil. The company has established a network of independent drug stores, Nu Health, and recently signed up Circa Pharmaceuticals to repackage a line of up to 120 products.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS081741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel